WO2005019442A2 - Verfahren zur reklonierung von produktionszellen - Google Patents
Verfahren zur reklonierung von produktionszellen Download PDFInfo
- Publication number
- WO2005019442A2 WO2005019442A2 PCT/EP2004/009204 EP2004009204W WO2005019442A2 WO 2005019442 A2 WO2005019442 A2 WO 2005019442A2 EP 2004009204 W EP2004009204 W EP 2004009204W WO 2005019442 A2 WO2005019442 A2 WO 2005019442A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- mammalian
- feeder
- cho
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 109
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 124
- 241000699800 Cricetinae Species 0.000 claims abstract description 56
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 39
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 33
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 210000004027 cell Anatomy 0.000 claims description 702
- 210000004962 mammalian cell Anatomy 0.000 claims description 138
- 239000002609 medium Substances 0.000 claims description 46
- 238000010367 cloning Methods 0.000 claims description 45
- 239000000047 product Substances 0.000 claims description 31
- 108091006047 fluorescent proteins Proteins 0.000 claims description 28
- 102000034287 fluorescent proteins Human genes 0.000 claims description 28
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 26
- 238000004113 cell culture Methods 0.000 claims description 22
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 17
- 230000000644 propagated effect Effects 0.000 claims description 11
- 238000004114 suspension culture Methods 0.000 claims description 11
- 239000006143 cell culture medium Substances 0.000 claims description 7
- 239000012679 serum free medium Substances 0.000 claims description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 6
- 239000012228 culture supernatant Substances 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 238000000151 deposition Methods 0.000 abstract description 19
- 230000008021 deposition Effects 0.000 abstract description 17
- 229960000074 biopharmaceutical Drugs 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 34
- 241000699666 Mus <mouse, genus> Species 0.000 description 32
- 230000012010 growth Effects 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 239000003623 enhancer Substances 0.000 description 15
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 230000008569 process Effects 0.000 description 12
- 230000005855 radiation Effects 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 239000003550 marker Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000699798 Cricetulus Species 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 238000010370 cell cloning Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- -1 Antibodies Proteins 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 241000699678 Mesocricetus Species 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 241001512733 Zoanthus sp. Species 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
- 241000699802 Cricetulus griseus Species 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000006271 Discosoma sp. Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 108010022394 Threonine synthase Proteins 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000005138 cryopreservation Methods 0.000 description 4
- 102000004419 dihydrofolate reductase Human genes 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000699673 Mesocricetus auratus Species 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 108700012411 TNFSF10 Proteins 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 108700009124 Transcription Initiation Site Proteins 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 235000021120 animal protein Nutrition 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 239000013587 production medium Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000003153 stable transfection Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- GLCCHZQEWYMOBT-UHFFFAOYSA-N 2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),3,5,7,11-pentaene-10,13-dione Chemical compound O=C1C=CC(=O)C2=C1C=C1N2C=C2N=C21 GLCCHZQEWYMOBT-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000242764 Aequorea victoria Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000006720 Clavularia sp. Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000242743 Renilla reniformis Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000053227 Themus Species 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- KVEAILYLMGOETO-UHFFFAOYSA-H dicalcium magnesium diphosphate Chemical compound P(=O)([O-])([O-])[O-].[Mg+2].[Ca+2].[Ca+2].P(=O)([O-])([O-])[O-] KVEAILYLMGOETO-UHFFFAOYSA-H 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 108010002685 hygromycin-B kinase Proteins 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000013337 sub-cultivation Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 101150024821 tetO gene Proteins 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 241000242763 Anemonia Species 0.000 description 1
- 241001512986 Anemonia majano Species 0.000 description 1
- 241000242762 Anemonia sulcata Species 0.000 description 1
- 241000242757 Anthozoa Species 0.000 description 1
- 102100023927 Asparagine synthetase [glutamine-hydrolyzing] Human genes 0.000 description 1
- 108010070255 Aspartate-ammonia ligase Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100031620 Cysteine and glycine-rich protein 3 Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241001512730 Discosoma striata Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 1
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 1
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004230 Neurotrophin 3 Human genes 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- 108090000095 Neurotrophin-6 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 1
- 108010035235 Phleomycins Proteins 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101000849522 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S13 Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 1
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 1
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001455 anti-clotting effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000013452 biotechnological production Methods 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000005315 distribution function Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 101150097231 eg gene Proteins 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940032018 neurotrophin 3 Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Definitions
- the present invention relates to the field of cell culture technology and relates to methods for the multiplication / cloning of cells, preferably cell lines, which are important for the production of biopharmaceuticals. Furthermore, the invention relates to methods for the production of proteins using cells which have been obtained and multiplied by means of single cell deposition, and to compositions which make it possible to multiply individual cells.
- biopharmaceuticals For the biotechnological production of biologically active or therapeutic proteins in mammalian cells, so-called “biopharmaceuticals”, the corresponding mammalian cells are stably transfected with DNA which codes for the respective biologically active protein (or its subunits).
- a pool is normally obtained after the transfection process of millions of differently transfected cells, therefore the decisive step in the production of efficient production cell lines lies in the selection and proliferation of cell clones, which on the one hand grow very stably and on the other hand show a high specific productivity of therapeutic protein (product formation etc.)
- cell clones which on the one hand grow very stably and on the other hand show a high specific productivity of therapeutic protein (product formation etc.)
- This process of single cell isolation and subcultivation is also called - cloning or recloning.
- the selection of transfected cells is possible, for example, by fluorescence-activated cell sorting (FACS), in that the expression of the therapeutic protein is linked, for example, to the expression of a marker protein.
- FACS fluorescence-activated cell sorting
- fluorescent proteins and their variants of Aequorea victoria, Renilla reniformis or other species such as the red, yellow, violet, green fluorescent proteins or their variants of non-bioluminescent organisms such as Discosoma sp., Anemonia sp., Clavularia sp ., Zoanthus sp. co-expressed together with the therapeutic protein in a cell.
- the fluorescence intensity allows conclusions to be drawn about the specific productivity and the growth behavior of the cells.
- recombinant production cells such as mouse myeloma (NSO), hamster ovary (CHO), or hamster kidney (BHK) cells, especially if these are adapted to growth in serum-free suspension cultures, i.e. under modern production-relevant cell culture conditions to be placed individually in culture vessels, for example in wells of microtiter plates, under serum-free culture conditions and to multiply effectively (recloning). If only a few cells, for example fewer than 5 cells, are placed in a culture vessel under serum-free conditions, these cells can usually not be reproduced, or at least no longer efficiently. The reason for this is assumed to be in the absence of cell-cell contacts, a higher nutrient / growth factor requirement with lower cell density and / or in the absence or insufficient concentration of diffusible signal and conditioning factors.
- NSO mouse myeloma
- CHO hamster ovary
- BHK hamster kidney
- the correspondingly obtained individual clones then have to be adapted to the serum-free growth in suspension culture, which is regularly associated with a high expenditure of time as well as with a changed productivity of the cell and product quality (see also Kaufmann et al., 2001; Mueller et al., 1999, among others) ).
- nutrient cells also called feeder cells
- the growth properties of cells can be positively influenced or some cell types can only be increased under cell culture conditions. Examples include human-mouse or mouse-mouse hybridoma cells (Hlinak et al 1988, US 5,008,198), primary keratinocytes (Rheinwald and Green, 1975; WO9954435), stem cells (Williams et al., 1988) and various tumor cells (Wee Eng Lim et al., 2002; Rexroad et al., 1997; Peng et al., 1996; Grigoriev et al., 1996; Sanchez et al., 1991; Butcher et al., 1988; Long et al., 1986; Shneyour et al., 1984; Pintus et al., 1983; Brodin et al., 1983).
- Feeder cells are mostly chemically or physically arrested cells that have stopped their ability to divide due to a special pretreatment, but are otherwise still vital for about 2 to 3 weeks on average. Feeder cells are therefore still able to release growth-promoting factors into the medium and can thus promote the initial growth of non-arrested cells or enable them in the case of different primary cells.
- the fee ⁇ fer cells are so-called "monolayers" in one Culture vessel plated out. The adherently growing cells to be cultivated are then plated onto or between the feec / er cells and cultivated under standard conditions.
- Feec / er cells can be removed, for example, by irradiation or treatment with mitomycin C (Azirino [2 ', 3': 3,4] pyrrolo [1, 2-a] indole-4,7-dione, 6-amino-8- [[(aminocarbonyl) oxy] methyl] -1, 1a, 2,8,8a, 8b-hexahydro-8a-methoxy-5-methyl-, [1aR- (1a.alpha., 8.beta., 8a.alpha ., ⁇ b.alpha.)] - (9CI) (Butcher et al, 1988)).
- mitomycin C Azirino [2 ', 3': 3,4] pyrrolo [1, 2-a] indole-4,7-dione, 6-amino-8- [[(aminocarbonyl) oxy] methyl] -1, 1a, 2,8,8a, 8b-hexahydro-8a
- An object of the present invention was to find an efficient recloning process which, starting from fewer than five cells, preferably from one (1) single cell, allows an increase in production-relevant mammalian cells under serum-free conditions and in suspension culture.
- the task was to provide appropriate methods for the recloning of CHO or BHK cells originally isolated from hamsters and for myeloma cells, for example NSO cells, originally isolated from mouse.
- Another object of the invention was to provide compositions which enable the appropriate recloning methods to be carried out, in particular those which allow recloning of hamster or mouse myeloma cells.
- a method for cloning cells characterized in that less than five, preferably one (1) or (2) mammalian cell (s), preferably Hamsters or mouse myeloma cells, in the presence of feec / er cells, preferably of autologous origin, are placed in a culture vessel under serum-free conditions and cultivated and multiplied under serum-free conditions.
- mammalian cell preferably Hamsters or mouse myeloma cells
- feec / er cells preferably of autologous origin
- Another embodiment of the invention relates to the use of hamster cells as feec / er cells in the event that the corresponding stored and to be cloned mammalian cells are also hamster cells, in particular CHO or BHK cells.
- Mouse myeloma cells are preferably used as feec / er cells if the cells which have been appropriately deposited and are to be cloned are NSO cells.
- Another aspect of the invention relates to a corresponding method for recloning CHO, BHK or NSO cells, which is characterized in that CHO cells are used as feec / er cells when the mammalian cells to be cloned are CHO cells.
- Cells act that BHK cells are used as feec / er cells if the mammalian cells to be cloned are BHK cells, and that NSO cells are used as feec / er cells if they are the mammalian cells to be cloned are NSO cells.
- the methods according to the invention are distinguished by a good recloning efficiency of greater than 10%, preferably greater than 20%, in particular for individually deposited cells.
- the recloning methods according to the invention have a recloning efficiency of greater than 30%, preferably greater than 40%, particularly preferably greater than 50%, more preferably greater than 60%, even more preferably greater than 70%, even more preferably greater than 80 %.
- recloning efficiencies from 10 to greater than 65% are considered efficient when recloning individually stored CHO cells, from 10 to greater than 50% when recloning individually stored BHK cells, and from 10 to greater than 45% when recloning individually stored NSO cells , If more than one (1) cell is deposited per culture vessel, for example two, three or four, the recloning efficiency for the respective cells is above the values specified for the recloning of CHO, BHK and NSO cells.
- Another aspect of the invention relates to a corresponding method for recloning mammalian cells, in particular hamsters or mouse myeloma cells, in which the cells to be cloned are multiplied in the presence of 100 to 200,000 feec / er cells per ml of medium.
- the present invention also relates to processes for the production of proteins, preferably recombinant proteins, in serum-free non-adherent growing mammalian cells which have been cultivated according to one of the cloning processes according to the invention, in particular the production of recombinant proteins in appropriately cloned hamsters or mouse myeloma cells such as CHO -, BHK, or NSO cells, under serum-free conditions, comprising the steps a) cultivation of mammalian cells which express a gene product of interest, under serum-free conditions which allow the corresponding cells to be grown; b) depositing in each case less than 5, preferably one (1) or 2, of the corresponding mammalian cells into one (1) cell culture vessel under serum-free conditions; c) multiplication of the correspondingly deposited cells in the presence of autologous feec / er cells under serum-free conditions; d) culturing the increased number of previously deposited cells under serum-free conditions under which the gene of interest is expressed; and e) recovering
- the mammalian cells can be separated manually or by FACS-based sorting, for example, and each placed in a cell culture vessel with feec / er cells.
- Non-adherently cultured feec / er cells are preferably used.
- the present invention relates to the basic use of hamster cells, preferably CHO or BHK cells, and of mouse myeloma cells, preferably of the NSO type, as feec / er cells. According to a preferred Embodiment, the present invention relates to the use of corresponding cells which are adapted to serum-free culture conditions.
- the present invention relates to compositions consisting of a serum-free cell culture medium, fewer than five divisible mammalian cells and feec / er cells autologous to the divisible mammalian cells.
- the divisible mammalian cells are cells which are adapted to the serum-free growth as a suspension culture.
- the composition contains only one (1) or two (2) mammalian cell (s) capable of dividing in the culture medium.
- the divisible mammalian cell (s) are hamster cells, such as CHO or BHK cells, or mouse myeloma cells, e.g. around NSO cells.
- the composition contains hamster cells, preferably CHO cells as feec / er cells, if the divisible mammalian cell (s) are CHO cells. If the divisible mammalian cell (s) are BHK cells, the composition also contains hamster cells, but preferably BHK cells as feec / er cells. If the divisible mammalian cell (s) are mouse myeloma cells, for example NSO cells, the composition also contains mouse myeloma cells as feec / er cells, preferably also in the case of NSO cells NSO cells as feec / er cells.
- the single cell deposition leads to stable, homogeneous cell clones, which is essential for the production of biopharmaceuticals, not least with regard to regulatory requirements for their approval as medicinal products.
- autologous feec / er cells for the recloning of production-relevant CHO, BHK or NSO cells, for example the use of hamster cells, preferably CHO or BHK cells, or mouse myeloma cells, preferably NSO Cells, a much lower risk of contamination with regard to human pathogens than the use of human or less well-characterized cells.
- Figure 1 shows the correlation between the energy dose used in the production of the feec / er cells and the cloning efficiency in the recloning of automated stored CHO-DG44 single cells.
- the cells were deposited on approximately 2,000 inactivated autologous feec / er cells. It can be seen from the graphics that feec / er cells irradiated with the energy dose of 20-500 Gy still release sufficient factors into the medium so that more than 65% of the deposited individual clones grow into colonies at 50 Gy.
- Figure 2 shows the productivity of antibody-expressing CHO-DG44 cultures obtained by limited dilution (left column) or single cell deposition (right column).
- the left column shows the productivity of 6 cultures, which were obtained by means of limited dilution.
- the right half shows the productivity of 6 single clones from the automated single cell storage.
- Three parallel experiments per cell clone / culture were carried out to determine productivity.
- the cloning by automated single clone storage resulted in a significantly lower dispersion in productivity.
- the subcultures cultivated in parallel and derived from a single clone show a significantly higher homogeneity with regard to their productivity in comparison to the subcultures obtained after limited dilution.
- Figure 3a shows the product titer of CHO-DG44 cell clones sorted and sorted according to different criteria.
- the bottom graphic A single cells were stored that only meet the "living cell” sorting criterion. This criterion was defined via the forward-side scatter application in the flow cytometer. A selection according to the fluorescence of the cells was not made and upper graphics B and C, in addition to the "living cell” sorting criterion, logically linked the "fluorescence of the cells” sorting criterion. The "fluorescence of the cells” sorting criterion was further specified via the fluorescence intensity. For this purpose, the top 20% fluorescent and on the other hand the top 5% fluorescent cell clones were placed individually. The shift to the right of histogram C shows that the proportion of highly expressing cell clones increases significantly when using the criterion top 5% fluorescent cells compared to the other sorting criteria used for A and B.
- cloning / recloning means in connection with cell culture a technique by means of which a cell population of identical cells can be obtained from an original cell.
- Single clones are genetically identical cells that originate from one (1) single cell.
- a cell population consisting of identical cells of the same origin is therefore also referred to as a "monoclonal cell population". It occurs during the cultivation of cells of the same origin for spontaneous genome changes, for example mutations and / or translocations, the individual cells of this cell population are nevertheless regarded as identical cells in the sense of the present invention, and the culture is understood as a monoclonal cell population.
- a pool of stably transfected cells (transfectants) is not a cell clone of the same lineage, i.e. not a monoclonal cell population, even if genetically identical starting cells are transfected with an identical nucleic acid.
- subclones / subcultures refers to different cell generations that arise from an original cell / culture by simply or multiple passages of the dividing cells.
- an “effective or efficient recloning” is understood to mean a cloning efficiency of at least 10%, preferably of at least 20%, more preferably of at least 30% and even more preferably of at least 40%. According to a particularly preferred embodiment of the present invention, a effective recloning a cloning with an efficiency of at least 50%, preferably of at least 60%, particularly preferably of at least 70% and even more preferably of at least 80%
- cloning efficiency is defined as the percentage of cells which, after being deposited, can form vital cell populations of preferably more than 50 cells. If, for example, 50 cells are distributed to 50 culture vessels during a cell sorting, 25 of these 50 individually deposited cells grow into cultures , the cloning efficiency is 50% (25 out of 50).
- divisible / expandable in the sense of the present invention describes the potential of a cell / cell population to be able to divide endlessly, but at least over 2, preferably 4, passages. This potential can be achieved, for example, by irradiation with [37] Cs or mitomycin C Treatment can be reduced or completely disrupted.
- derivative / descendant refers to cells which are genetically attributable to a specific starting cell and are produced, for example, by subcultivation (with or without selection pressure) and / or are generated by genetic manipulation. Re-isolations of cells of the same cell type are also covered by the term "derivative / descendant".
- CHO cell lines are derivatives / descendants of the hamster ovary cells from Cricetulus griseus isolated by Puck et al., 1958, regardless of whether they were obtained by subculturing, re-isolation or genetic manipulation.
- autologous feec / er cell means that both the feec / er cell and the cell to be cultivated in the presence of this feec / er cell are taxonomically from the same origin. If the cell to be cultivated is, for example, one Hamster cell (subfamily Cricetinae), preferably around a cell of the genus Cricetulus or Mesocricetus, for example around a CHO or BHK cell, so each feec / er cell originally isolated from this subfamily adds an autologous feec / er cell to it Hamster cells of the subfamily Cricetinae.
- Hamster cell subfamily Cricetinae
- the term "autologous feec / er cell” means that both feec / er cell and the cell to be cultivated are taxonomically from the same genus or were originally isolated from the same genus (cell from Cricetulus or Mesocricetus).
- each feec / er cell originally isolated from the respective genus provides an autologous feec / er
- a particularly preferred embodiment is an “autologous feeder cell” if the feec / er cell and the cell to be cultivated originate from the same species and have the same tissue tropism (eg ovary cells from Cricetulus griseus - CHO cells).
- a feec / er cell is an autologous feec / er cell if both the feec / er cell and the cell to be cultivated originate from the same basic cell, for example if both cells are originally CHO-DG44 cells or descendants of this cell.
- the feec / er cell mediates the same resistance, for example to antibiotics, as the cell to be cultivated. This is particularly advantageous if the cells are deposited in the presence of a selection agent, for example an antibiotic.
- serum-free means culture media as well as cultivation conditions, which are characterized in that cells are cultivated in the absence of animal and / or human serum, preferably in the absence of any proteins isolated from serum, preferably in the absence of proteins not obtained recombinantly
- the expression “cells adapted to serum-free conditions” means cells that can be grown in the absence of animal or human serum or serum proteins.
- protein-free means that the culture medium contains no animal proteins, and proteins isolated from bacteria, yeasts or fungi are not to be understood as animal proteins.
- chemically defined describes a cell culture medium which is serum-free, preferably also protein-free, and which consists of chemically defined substances. Chemically defined media thus consist of a mixture of predominantly pure individual substances.
- An example of a chemically defined medium is, for example, the CD -CHO medium from Invitrogen (Carlsbad, CA, US).
- a cell that can be cultivated in suspension refers to cells that have been adapted to growth in liquid cultures (“suspension cultures”) and whose ability to adhere to vessel surfaces, for example to cell culture dishes / bottles, has been restricted or lost.
- Cells which are adapted to both serum-free growth and to growth in suspension are referred to as "cells which are adapted and non-adherent to serum-free medium”. If feec / er cells are produced from such cultures, it is a matter of fact by definition these cells are "feec / er cells adapted and adapted to serum-free medium”.
- the present invention relates to a method for cloning cells, characterized in that less than five, for example four, three, two or one (1) mammalian cell (s) in the presence of feec / er cells, preferably autologous feec / er Cells, placed in a culture vessel under serum-free conditions and cultivated and grown under serum-free conditions.
- the present invention relates to a corresponding method for cloning mammalian cells, characterized in that one (1) or two mammalian cell (s) per culture vessel are deposited under serum-free conditions and cultivated in the presence of autologous feec / er cells under serum-free conditions will become).
- a further preferred embodiment is a method for cloning single cells, characterized in that one (1) single mammalian cell is placed in a culture vessel in the presence of autologous feeder cells under serum-free conditions, cultivated under serum-free conditions and multiplied.
- the deposited and to be cultivated cell is in each case a cell growing in suspension culture.
- each growing cell population is a monoclonal cell population and the method is a method for direct single cell cloning. If more than one (1) individual cell is placed and propagated per culture vessel, for example two, three or four cells, the growing cell populations are so-called mixed clones.
- mammalian cells of the Murinae subfamily for example the Mus genus or the Cricetinae subfamily, for example the Cricetulus or Mesocricetus genera, and cell lines isolated from them, including their derivatives / derivatives, can be propagated and also cloned.
- the method according to the invention is preferably suitable for the multiplication / cloning of hamster cells or mouse myeloma cells and of stable cell lines derived therefrom. Accordingly, the present invention relates to a method for cloning cells in the presence of feeder cells, preferably autologous feeder cells, characterized in that the mammalian cells which are appropriately deposited and are to be cloned are hamster or mouse myeloma cells.
- feeder cells preferably autologous feeder cells
- the methods according to the invention relate to methods for the multiplication / cloning of hamster cells of the genus Cricetulus (Chinese dwarf hamster) and of stable cell lines isolated from this genus or derived from the isolated cells, for example CHO, CHO-K1, CHO-DUKX, CHO-DUKX B1 or CHO-DG44 cells as well as derivatives / descendants of these cell lines.
- a method according to the invention is particularly advantageous in which CHO-DG44, CHO-DUKX, and CHO-K1, in particular CHO-DG44 and CHO-DUKX cells are multiplied and cloned in the presence of autologous feeder cells.
- the present invention preferably relates to a method for the multiplication and cloning of CHO or BHK cells, and also their derivatives / derivatives, characterized in that fewer than five, for example four, three, two, or preferably only one (1) cell ( n) placed in the presence of autologous feeder cells in a culture vessel under serum-free conditions and cultivated and grown under serum-free conditions.
- the present invention relates to a method for the multiplication and in particular for the cloning of mouse myeloma cells, preferably from Mus musculus and from stable cell lines isolated or derived therefrom, for example NSO and Sp2 / 0 cells and derivatives / derivatives of these cell lines.
- This method is also characterized in that less than five, for example four, three, two, or preferably only one (1) of these cells are placed in a culture vessel in the presence of autologous feeder cells under serum-free conditions and cultivated and propagated under serum-free conditions (becomes).
- hamster and mouse cells that can be multiplied and cloned according to the invention are given in Table 1 below.
- other mammalian cells including cell lines from humans, mice, rats, monkeys, or rodents other than mice or hamsters, can also be multiplied or cloned by one of the methods according to the invention.
- the corresponding mammalian cells are preferably established, cultivated and deposited under serum-free conditions. If necessary, these steps take place in media which are free from animal proteins / peptides and / or chemically defined.
- media which are free from animal proteins / peptides and / or chemically defined.
- Examples of commercially available media are Ham 's F12 (Sigma, Deisenhofen, DE), RPMI-1640 (Sigma), Dulbecco 's Modified Eagle 's Medium (DMEM; Sigma), Minimal Essential Medium (MEM; Sigma), Iscove 's Modified Dulbecco's medium (IMDM; Sigma), CD-CHO (Invitrogen, Carlsbad, Ca., USA), CHO-S-SFM-II (Invitrogen), serum-free CHO medium (Sigma), and protein-free CHO medium (Sigma).
- Each of these media can optionally be supplemented with various compounds, e.g. hormones and / or other growth factors (e.g. insulin, transferrin, epidermal growth factor, insulin-like growth factor), salts (e.g. sodium chloride, calcium, magnesium, phosphate), buffers (e.g. HEPES) , Nucleosides (eg adenosine, thymidine), glutamine, glucose or other equivalent nutrients, antibiotics and / or trace elements.
- hormones and / or other growth factors e.g. insulin, transferrin, epidermal growth factor, insulin-like growth factor
- salts e.g. sodium chloride, calcium, magnesium, phosphate
- buffers e.g. HEPES
- Nucleosides eg adenosine, thymidine
- glutamine glucose or other equivalent nutrients
- antibiotics e.g. antibiotics
- feeder cells for the cultivation of cells has been described in connection with the cultivation of adherently growing cells (e.g. Wee Eng Lim et al., 2002; Rexroad et al., 1997; Peng et al., 1996; Grigoriev et al. , 1996; Sanchez et al., 1991; Butcher et al., 1988; Long et al., 1986; Shneyour et al., 1984; Pintus et al., 1983; Brodin et al., 1983.
- Adherent feeders are Cells placed in a culture vessel or on a support as a single cell layer (Engl. Monolaye ⁇ and the cells to be cultivated on this monolayer cultivated. Since the feeder cells have lost their ability to grow further (either naturally or by artificial action), the cells that are cultivating multiply without being overgrown by the feeder cells, in which case both feeder cells and the cells to be cultivated are adherently growing cells.
- the present invention enables the proliferation of cells growing in suspension, either using adherent autologous feeder cells or according to a further preferred embodiment using autologous feeder cells which are likewise kept in suspension.
- the use of autologous feeder cells kept in suspension is particularly preferred if both the feeder cell (s) and the cell (s) to be cultivated originate from the same basic cell, for example if both cells are originally cells that are have been adapted to the growth in suspension.
- the present invention thus also relates to a method for the multiplication / cloning of the mammalian cells described above, characterized in that the cells to be cultivated are deposited, cultivated and multiplied in the presence of autologous feeder cells which are kept in suspension.
- a corresponding method is particularly preferred, which is characterized in that the cell (s) to be cultivated are cell (s) which are adapted to the growth in suspension.
- a corresponding method for the multiplication / cloning of mammalian cells is further preferred, characterized in that the cell deposition and the cell multiplication of the deposited mammalian cells is carried out in a serum-free and / or protein-free and / or chemically defined suspension culture.
- the number of autologous feeder cells to be used in the multiplication / cloning of the mammalian cells described here basically depends on the nature of the mammalian cell to be multiplied and cloned and can be determined by simple titration experiments for each cell type.
- the methods according to the invention for the multiplication / cloning of mammalian cells are carried out, for example, in the presence of at least more than 100 autologous feeder cells per ml of medium, preferably in the presence of 100 to 200,000 autologous feeder cells per ml of medium.
- the multiplication / cloning of the mammalian cells takes place in the presence of 500 to 50,000 autologous feeder cells per ml of medium.
- the multiplication / cloning of the mammalian cells is carried out in the presence of 500 to 10,000 autologous feeder cells per ml of medium, preferably in the presence of 2,000 to 10,000 autologous feeder cells per ml of medium.
- the present invention relates to methods for the multiplication / cloning of mammalian cells, characterized in that hamster cells, preferably of the Cricetinae subfamily, more preferably of the Cricetulus or Mesocricetus genera, are used as feeder cells when the mammalian cells that are deposited and to be multiplied / cloned are CHO or BHK cells, and that mouse myeloma cells are used as feeder cells if the mammalian cells that are deposited and to be multiplied / cloned are NSO cells
- a method for multiplying / cloning mammalian cells is further preferred, characterized in that CHO cells are used as feeder cells if the deposited and to be multiplied / cloning mammalian cells are CHO cells that BHK cells as feeder cells are used when it is in the deposited and reproductive / cloning mammals cells are BHK cells and that NSO cells are used as feeder cells
- the use of autologous feeder cells which also have the resistance-mediating selection marker gene, is suitable, since this means that the feeder cells die faster in the presence of the selection agent can be prevented.
- the present invention also relates to methods for cloning cells, in particular the hamsters or mouse myeloma cells mentioned above, characterized in that fewer than five, for example four, three, two or one (1) of this mammalian cell (s) in the presence of autologous feeder cells, placed in a culture vessel under serum-free conditions and cultivated and grown under serum-free conditions, the autologous feeder cells and the deposited mammalian cell (s) each having at least one selection marker gene which is resistant mediated against a selection agent, and at least the multiplication of the mammalian cell (s) to be cloned takes place under serum-free conditions in the presence of said selection agent, to which both the feeder cell and the mammalian cell to be cloned are resistant.
- the autologous feeder cells can be produced, for example, by irradiation with a radioactive radiation source, for example by irradiation with the cesium isotope 137 ( 137 Cs). Irradiation with an energy dose between 1 and 1,000 Gy is advantageous for the methods described here for the multiplication / cloning of mammalian cells in the presence of autologous feeder cells. It is particularly advantageous here to use an energy dose between 10 and 500 Gy, further advantageously between 20 and 200 Gy. In connection with the cloning of CHO cells, it has been shown that the use of autologous feeder cells, preferably CHO cells, is advantageous and leads to an efficient cloning efficiency which has been irradiated with an energy dose between 1 and 500 Gy.
- autologous feeder cells which were irradiated with an energy dose between 20 and 100 Gy, preferably with about 50 Gy, proved to be particularly advantageous.
- the optimal energy dose for each cell can be determined experimentally by treating feeder cells with different total radiation doses and, in analogy to the method described in the exemplary embodiments, the cloning efficiency is determined in each case as a function of the radiation dose.
- gamma radiation with 137 Cs and 60 Co cobalt isotope 60
- treatment with UV radiation, electron radiation, radioactive radiation, neutron radiation and microwave radiation is also suitable, for example.
- the feeder cells can be used directly or after cryopreservation, for example in liquid nitrogen, in one of the methods according to the invention for the multiplication / cloning of mammalian cells.
- Methods for cryopreservation of mammalian cells are known to the person skilled in the art and are described, for example, in Freshney (Hers.), Animal Cell culture - a practical approach, IRL-Press 1986, pages 73-78, to which reference is made here in terms of content.
- the present methods are suitable for multiplying the deposited mammalian cells to a density of 1 ⁇ 10 5 to 4 ⁇ 10 6 / mL medium in the culture vessel in which they were originally deposited.
- a first preferably takes place Passenging with a cell density of 2 x 10 5 to 8 x 10 5 / mL medium, in particular with a cell density of 2 x 10 5 to 5 x 10 5 / mL medium.
- the methods according to the invention for the multiplication / cloning of the mammalian cells described here are characterized by an efficient recloning efficiency, so that the present invention relates to methods for the multiplication / recloning of mammalian cells, characterized in that the cloning efficiency is at least 10%, preferably at least 20%, more preferred is at least 30% and even more preferably at least 40%.
- the present invention relates to methods for multiplying / recloning mammalian cells, characterized in that the recloning efficiency is at least 50%, preferably at least 60% and particularly preferably at least 70% and even more preferably at least 80%.
- the present invention also relates to methods for the multiplication / recloning of CHO cells, which are characterized in that the recloning efficiency in the recloning of deposited CHO cells is 10 to greater than 65%, preferably greater than 20%, particularly preferably greater than 30% is preferably greater than 40%, even more preferably greater than 50%, in particular greater than 60%.
- the present invention also relates to methods with somewhat lower recloning efficiencies for the cell types specified in each case.
- the present invention relates to processes for the production of one or more products (polypeptides, proteins, nucleic acids, etc.), preferably recombinant products, in cells which are multiplied / recloned by one of the processes described above.
- the prerequisite is that the cell in question contains one or more genes of interest that code for one or more products to be produced.
- the corresponding cell is preferably a CHO, BHK or NSO cell and Derivatives / descendants of these cell lines. However, this can also be any other cell, for example one of the cells listed in Table 1.
- the gene (s) of interest to be produced can be genes that are naturally present in the host cell or genes that are artificially introduced into the cells.
- any sequence or gene that is introduced into a cell is referred to as a "heterologous sequence” or “heterologous gene” with respect to that cell, even if the sequence or gene to be introduced is identical to an endogenous sequence or is an endogenous gene of the cell.
- a hamster actin gene that is introduced into a hamster cell is by definition a heterologous gene. If this heterologous gene codes for a gene of interest, one also speaks of a "heterologous gene of interest”.
- a heterologous gene of interest can be introduced into the cell in various ways, for example by viral transformation, transfection or else by microinjection.
- the heterologous gene of interest can be introduced into the cell as linear DNA or as part of an expression vector.
- a large number of eukaryotic expression vectors are known which allow multiple cloning sites for the introduction of one or more heterologous genes and their expression.
- Commercial providers include companies such as Stratagene, La Jolla, CA, USA; Invitrogen, Carlsbad, CA, USA; Promega, Madison, Wl, USA or BD Biosciences Clontech, Palo Alto, CA, USA.
- the cells are transfected with a DNA or an expression vector which codes for one or more genes of interest, using conventional methods, as described, for example, in Sambrook et al., 1989 or Ausubel et al., 1994.
- Suitable transfection methods are, for example, liposome-mediated transfection, calcium phosphate coprecipitation, electroporation, polycations (eg DEAE-dextran) -mediated transfection, protoplast fusion, microinjection and viral infections.
- a stable transfection is preferably carried out, the DNA molecules either being integrated into the genome of the host cell or an artificial chromosome / minichromosome or are contained in a stable manner episomally in the host cell.
- the transfection method that the optimal Transfection frequency and expression of one or more heterologous genes of interest in the respective cell is preferred.
- the heterologous gene of interest is usually functionally linked to a promoter that enables the transcription of the gene of interest, as well as other regulatory elements that enable transcription and translation (expression) of the gene of interest or increase its efficiency.
- a “promoter” is a polynucleotide sequence that enables and controls the transcription of the genes or sequences functionally linked to it.
- a promoter contains recognition sequences for the binding of the RNA polymerase and the initiation site of the transcription (transcription initiation site).
- transcription initiation site For the expression of a desired sequence in A suitable, functional promoter must be selected in each case for a specific cell type or a host cell.
- the person skilled in the art knows a large number of promoters from various sources, including constitutive, inducible and repressible promoters. They are stored in databases, for example GenBank, and can be used as stand-alone or within elements cloned from polynucleotide sequences can be obtained from commercial or individual sources.
- inducible promoters the activity of the promoter can be reduced or enhanced in response to a signal.
- An example of an inducible P romotor is the tetracycline (tet) promoter. This contains tetracycline operator sequences (tetO) that can be induced by a tetracycline-regulated transactivator protein (tTA). The binding of tTA to tetO is inhibited in the presence of tetracycline.
- tetO tetracycline operator sequences
- tTA tetracycline-regulated transactivator protein
- further inducible promoters are the jun, fos, metallothionine and heat shock promoters (see also Sambrook et al., 1989; Gossen et al., 1994).
- the promoters that are particularly well suited for high expression in eukaryotes are the hamster ubiquitin / S27a promoter (WO 97/15664), the SV40 early promoter, the adenovirus major late promoter, and the mouse metallothionin I promoter , the long terminal repeat region of the Rous Sarcoma virus and the early promoter of the human cytomegalovirus.
- heterologous mammalian promoters are the actin, immunoglobulin, or heat shock promoter (s).
- the promoter can be functionally linked to enhancer sequences in order to increase the transcription activity.
- One or more enhancers and / or several copies of an enhancer sequence can be used for this, for example a CMV or SV40 enhancer.
- enhancer denotes a polynucleotide sequence which acts in cis localization on the activity of a promoter and thus stimulates the transcription of a gene functionally linked to this promoter.
- the action of the enhancers is position and orientation independent and can thus be positioned in front of or behind a transcription unit, within an intron or even within the coding region.
- the enhancer can be located both in the immediate vicinity of the transcription unit and at a considerable distance from the promoter. A physical and functional overlap with the promoter is also possible.
- enhancers are known to the person skilled in the art from various sources (and are stored in databases such as GenBank, for example SV40 enhancer, CMV enhancer, polyoma enhancer, adenovirus enhancer) and are available as independent elements or elements cloned within polynucleotide sequences r (e.g. deposited at ATCC or from commercial and individual sources).
- a variety of promoter sequences also include enhancer sequences, e.g. the commonly used CMV promoter.
- the human CMV enhancer is one of the strongest enhancers identified to date.
- An example of an inducible enhancer is the metallothionein enhancer, which can be stimulated by glucocorticoids or heavy metals.
- the regulatory elements include promoters, enhancers, termination and polyadenylation signals and other expression control elements. Both inducible and constitutive regulatory sequences are known for the different cell types. "Transcription regulatory elements" usually include a promoter upstream of the gene sequence to be expressed, transcription initiation and termination sites, and a polyadenylation signal.
- transcription initiation site refers to a nucleic acid in the construct that corresponds to the first nucleic acid that is incorporated into the primary transcript, ie the mRNA precursor. The transcription initiation site can overlap with the promoter sequences.
- transcription termination site refers to a nucleotide sequence that is normally present at the 3 'end of the gene of interest or of the gene segment to be transcribed and which causes the transcription to be terminated by RNA polymerase.
- polyadenylation signal is a signal sequence which causes the cleavage at a specific site at the 3 'end of the eukaryotic mRNA and the post-transcriptional incorporation of a sequence of about 100-200 adenine nucleotides (polyA tail) at the cleaved 3' end.
- the polyadenylation signal comprises the sequence AATAAA about 10-30 nucleotides upstream of the cleavage site and a downstream sequence.
- Various polyadenylation elements are known, for example tk polyA, SV40 late and early polyA or BGH polyA (described for example in US Pat. No. 5,122,458).
- Translation regulatory elements include a translation initiation site (AUG), a stop codon, and a polyA signal for each polypeptide to be expressed.
- AUG translation initiation site
- stop codon a polyA signal for each polypeptide to be expressed.
- the gene of interest usually contains a signal sequence encoding a signal precursor peptide that transports the synthesized polypeptide to and through the ER membrane, often, but not always, on the amine oterminus of the secreted protein and is cleaved by signal peptidases after the protein has been passed through the ER membrane has been.
- the gene sequence will usually, but not necessarily, contain its own signal sequence. If the native signal sequence is not present, a heterologous signal sequence can be introduced in a known manner. Numerous such signal sequences are known to the person skilled in the art and are stored in sequence databases such as GenBank and EMBL.
- Gene products of interest can include proteins / polypeptides, e.g. Antibodies, enzymes, cytokines, lymphokines, adhesion molecules, receptors and their derivatives or fragments are, however, not restricted to these. In general, all polypeptides that act as agonists or antagonists and / or can find therapeutic or diagnostic use are significant.
- proteins / polypeptides e.g. Antibodies, enzymes, cytokines, lymphokines, adhesion molecules, receptors and their derivatives or fragments are, however, not restricted to these. In general, all polypeptides that act as agonists or antagonists and / or can find therapeutic or diagnostic use are significant.
- polypeptides is used for amino acid sequences or proteins and denotes polymers of amino acids of any length. This term also includes proteins which are modified post-translationally by reactions such as, for example, glycosylation, phosphorylation, acetylation or protein processing.
- the structure of the polypeptide can be, for example, by Substitutions, deletions or insertion of amino acids, fusion with other proteins, can be modified while maintaining its biological activity.
- proteins are insulin; Insulin-like growth factor (IGF-I or IGF-II); human growth hormone (hGH) and other growth factors such as VEGF, EGF, TGF, e.g. TGF-alpha and beta, including ⁇ 1, ⁇ 2, ⁇ 3, ⁇ 4 and ⁇ 5; Tissue plasminogen activator (tPA); Erythropoietin (EPO); Thrombopoietin (TBO); Cytokines, for example interleukins (IL) such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL- 11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18; Interferon (IFN) alpha, beta, gamma, omega or tau; Tumor necrosis factor (TNF) such as TNF-alpha, beta, gamma, CD40 lig
- coagulation factors such as factor VII, factor VIII, factor IX, from Willebrands factor
- Anti-clotting factors such as protein C; Enekephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1-alpha); (human) serum albumin, Cell adhesion molecules such as LFA-1, Mac-1, p150.95, VLA-4, ICAM-1, ICAM-2, ICAM-3, VCAM, or ⁇ V / ⁇ 3 integrin including ⁇ or ⁇ subunits; Blood group antigens; flk2 / 3 receptor; OB receptor; MLP receptor; CTLA-4; Apo-2L receptors such as Apo-2; Transforming growth factor (TGF); CD proteins, T cell receptors; viral antigens such as the gp120 of HIV; Tumor-associated antigens such as, for example, HER2, HER3 or HER4 receptor, rheumatoid factors, for example NGF-
- antibodies are monoclonal, polyclonal, multispecific and single chain antibodies and fragments thereof, such as e.g. Fab, Fab ', F (ab'), Fc and Fc 'fragments, light (L) and heavy (H) immunoglobulin chains and their constant, variable or hypervariable regions as well as Fv and Fd fragments (Chamov et al., 1999 ).
- the antibodies can be of human or non-human origin. Humanized and chimeric antibodies are also suitable.
- fragment antigen-binding Fab
- fragment antigen-binding Fab
- They can, for example, be generated from conventional antibodies by treatment with a protease, such as papain, or else by DNA cloning.
- Other antibody fragments are F (ab ') 2 fragments, which can be produced by proteolytic digestion with pepsin.
- the variable region of the heavy and light chain are frequently linked to one another by means of a short peptide fragment of approx. 10-30 amino acids, particularly preferably 15 amino acids. This creates a single polypeptide chain in which VH and VL are linked by a peptide linker.
- Such antibody fragments are also referred to as a single-chain Fv fragment (scFv). Examples of scFv antibodies are known and described, see for example Huston et al. (1988).
- multimeric scFv derivatives have been developed in recent years to produce multimeric scFv derivatives.
- the intention is to generate recombinant antibodies with improved pharmacokinetic properties and increased binding avidity.
- these are produced as fusion proteins with multimerization domains.
- multimerization domains e.g. the CH3 region of an IgG or coiled coil structure act like the leucine zipper domains.
- the interaction between the VH and VL regions of the scFv fragment is used for multimerization (eg slide , Tri- and pentabodies).
- a person skilled in the art refers to a bivalent homodimeric scFv derivative as “diabody”.
- the shortening of the peptide linker in the scFv molecule to 5-10 amino acids results in the formation of homodimers by superimposition of VH / VL chains Examples of diabodies can be found in the literature, for example in Perisic et al. (1994).
- minibody a bivalent, homodimeric scFv derivative as “minibody”. It consists of a fusion protein which contains the CH3 region of an immunoglobulin, preferably IgG, particularly preferably IgG1, as a dimerization region. This connects the scFv fragments via a hinge. Region, also from IgG, and a linker region, examples of such minibodies are described in Hu et al. (1996).
- trimer the person skilled in the art describes a trivalent homotrimeric scFv derivative (Kortt et al., 1997).
- the direct fusion of VH-VL without using a linker sequence leads to the formation of trimers.
- the fragments which the person skilled in the art calls mini-antibodies and which have a bi-, tri- or tetravalent structure are also derivatives of scFv fragments.
- the multimerization is achieved via di-, tri- or tetrameric "coiled coil” structures (Pack et al., 1993 and 1995; Lovejoy et al., 1993).
- selection marker genes can also be transfected with one or more selection marker genes.
- selection marker genes including bifunctional (positive / negative) markers, have been described in the literature (see e.g. WO 92/08796 and WO 94/28143).
- selection markers that are commonly used in eukaryotic cells include the genes for aminoglycoside phosphotransferase (APH), hygromycin phosphotransferase (HYG), dihydrofolate reductase (DHFR), thymidine kinase (TK), glutamine synthetase, asparagine synthetase and genes that confer resistance to neomycin (G418), puromycin, histidinol D, bleomycin, phleomycin and zeocin. These genes can be introduced into the cell together with the gene of interest or separately. They are preferably also introduced into the cells via expression vectors. Appropriately modified cells can now be cultivated in the presence of one or more suitable selection agents which selectively prefer cells in growth which contain and express a corresponding selection marker gene.
- FACS fluorescence-activated cell sorting
- the fluorescent proteins also enable FACS-based isolation of individual mammalian cells.
- Correspondingly detected cells can be automatically identified as a single cell or into several cells, for example with the aid of a laser, for example with an argon laser (488 nm) and for example with a flow cytometer equipped with an autoclone unit (Coulter EPICS Altra, Beckman-Coulter, Miami , FL, USA), in culture vessels.
- a laser for example with an argon laser (488 nm) and for example with a flow cytometer equipped with an autoclone unit (Coulter EPICS Altra, Beckman-Coulter, Miami , FL, USA), in culture vessels.
- Sorting can also be carried out using magnetic beads.
- the cells are labeled using, for example, antibodies which are coupled to magnetic beads. This allows cells to be sorted according to defined properties.
- the FACS-based isolation of cell clones which have been deposited by one of the methods described here and which co-express a fluorescent protein and a gene of interest is particularly advantageous.
- the expression of the fluorescent protein and the gene of interest are functionally linked.
- Such a functional link exists, for example, if the two genes are in a close spatial arrangement, so that the expression rates of the two genes correlate with one another, for example after transient or stable transfection of a host cell.
- the corresponding cell clones, which show a high expression of fluorescent protein also have a high expression rate of the gene of interest due to the functional linkage.
- the fluorescent protein can be, for example, a green, blue-green, blue, yellow or other-colored fluorescent protein.
- GFP green fluorescent protein
- a special example is the green fluorescent protein (GFP) from Aequorea victoria or Renilla reniformis and mutants developed from it; see, for example, Bennet et al. (1998); Chalfie et al. (1994); WO 01/04306 and the literature cited there. Further fluorescent proteins and genes coding therefor are described in WO 00/34318, WO 00/34326, WO 00/34526 and WO 01/27150, which are incorporated herein by reference.
- fluorescent proteins are fluorophores from non-bioluminescent organisms of the species Anthozoa, for example from Anemonia majano, Clavularia sp., Zoanthus sp. I, Zoanthus sp. II, Discosoma striata, Discosoma sp. "Red”, Discosoma sp. "Green”, Discosoma sp. “Magenta”, Anemonia sulcata.
- the fluorescence proteins used can consist of the wild-type proteins, natural or genetically engineered mutants and variants, their fragments, derivatives or, for example, variants fused with other proteins or peptides.
- the mutations introduced can change, for example, the excitation or emission spectrum, the formation of chromophores, the extinction coefficient or the stability of the protein. Codon optimization can also improve expression in mammalian cells or other species.
- the fluorescent protein can also be used in fusion with a selection marker, preferably with an amplifiable selection marker such as, for example, dihydrofolate reductase (DHFR).
- DHFR dihydrofolate reductase
- the selection step can be carried out on cell populations or with pre-sorted cell populations / cell clones.
- One or more, preferably one (1), two, three or four cells can be deposited per cell culture vessel.
- the cells are preferably deposited in serum-free medium, particularly preferably in chemically defined medium, in the presence of autologous feeder cells. Suitable media and methods according to the invention for cell deposition using autologous feeder cells are discussed in detail elsewhere in this application.
- two or more sorting steps can also be carried out, with the cells between the individual sorting steps over a certain period of time, e.g. about two weeks as pools, cultivated and propagated in a suitable medium.
- the recloned cells are preferably grown in a serum-free culture medium and in suspension culture under conditions that allow expression of the gene of interest. If the gene of interest is under the control of constitutive promoters, for example, it is not necessary to add special inducers. If the expression of the gene is of interest, for example, under the control of inducible promoters, the cell culture medium has a corresponding inducer which is sufficient but not toxic Admit concentration.
- the cells can be expanded as desired by multiple sub-passengers and transferred to suitable cell culture vessels.
- the gene product (s) are produced either as a cellular, membrane-bound or as a secretory product.
- the product of interest is preferably obtained as a secreted gene product from the cell culture medium. If a protein or polypeptide is expressed without a secretion signal, the gene product can also be isolated from cell lysates. In order to obtain a pure, homogeneous product which is essentially free of other recombinant proteins and host cell proteins, usual cleaning steps are carried out. To do this, cells and cell debris are often first removed from the culture medium or lysate. The desired gene product can then be freed from contaminating soluble proteins, polypeptides and nucleic acids, e.g.
- a further aspect of the present invention consequently relates to a method for producing one or more products in mammalian cells under serum-free conditions, characterized in that (i) mammalian cells contain a gene of interest which codes for a protein of interest; (ii) the mammalian cells are cultured under serum-free conditions that allow the mammalian cells to multiply; (iii) less than five, preferably four, three, two or one (1) of said mammalian cell (s) are placed in a cell culture vessel under serum-free conditions; (iv) the correspondingly deposited mammalian cells are multiplied in the presence of autologous feeder cells under serum-free conditions; (v) culturing the replicated cells under serum-free conditions under which the gene of interest is expressed; and (vi) the gene product is then isolated and purified from the cells or the culture supernatant.
- this method is / are under Point (iii) placed only one (1) single or two (2) of the mammalian cells per cell culture vessel.
- a method is particularly preferred in which only one (1) single mammalian cell is deposited under point (iii).
- the cells can be deposited manually or automatically, for example using FACS-based cell sorting.
- the mammalian cell is a transfected mammalian cell into which the gene of interest has been introduced.
- the present invention also relates to a method for producing recombinant gene products, characterized in that, prior to step (i) of the method described above, the mammalian cells are transfected with a nucleic acid which codes at least for a gene of interest. Stable transfection of the corresponding mammalian cell is preferred.
- the present invention also relates to a FACS-based sorting of single and deposition of single or multiple mammalian cells, preferably less than 5, more preferably 4, 3, 2 or 1 mammalian cell (s) that are a protein of interest express, the cell sorting and cell deposition preferably taking place as a function of the expression rate of the fluorescent protein co-expressed in the mammalian cell, the expression of which is functionally linked to the expression of the protein of interest.
- the present invention also relates to a method for producing a recombinant protein in mammalian cells under serum-free conditions, characterized in that i) the mammalian cells are transfected with a gene which codes for a protein of interest; ii) the mammalian cells are transfected with a gene encoding a fluorescent protein, the expression of the gene encoding a fluorescent protein preferably being functionally linked to the expression of the gene of interest; iii) the transfected mammalian cells are cultivated under serum-free conditions which allow the transfected cells to multiply and the expression of at least the fluorescent protein; iv) in each case less than 5, preferably 4, 3, 2 or 1 (one) transfected mammalian cell (s) are placed in a cell culture vessel with autologous feeder cells after FACS-based cell sorting under serum-free conditions, the FACS-based cell sorting based on the expression rates of the fluorescent protein; v) the correspondingly deposited cells are multiplied in the presence of
- only one (1) individual cell per culture vessel is placed and multiplied in step iv).
- Preferably only those cells are sorted out under point iv) which belong to the 20% cells with the highest expression rate of fluorescent protein.
- this means that the brightest 20% of the fluorescent cells are sorted out (20% the most fluorescent cells).
- only the brightest 5%, preferably the brightest 3%, or only the brightest 1% of the fluorescent cells of a cell mixture are sorted out. As shown in Figures 3a and 3b, this leads to an accumulation of cell clones with a comparable high expression rate of the gene of interest.
- the FACS-based single cell deposition enables homogeneous cell clones to be identified and propagated, which have a comparable high expression rate for a gene of interest, which in turn are the starting point for further optimization steps (eg gene amplification).
- a corresponding method for producing one or more recombinant products in cloned mammalian cells is further preferred, characterized in that the mammalian cells are hamster or mouse myeloma cells, preferably CHO, BHK or NSO cells. as well as derivatives / descendants of these cell lines.
- the feeder cells are cells adapted to serum-free medium and are not adherently cultured. Further preferred in connection with the production method described above is the use of hamster cells as feeder cells if the mammalian cell (s) that have been deposited and are to be multiplied / cloned are CHO or BHK cells, and the use of mouse cells.
- Myeloma cells as feeder cells provided that they are deposited and too multiplying / cloning mammalian cell (s) are NSO cells.
- a corresponding method is particularly preferred which is characterized in that CHO cells are used as feeder cells if the mammalian cell (s) which have been deposited and are to be multiplied / cloned are CHO cells, that is BHK cells can be used as feeder cells if the mammalian cell (s) that have been deposited and are to be cloned and replicated are BHK cells and that NSO cells are used as feeder cells if the deposited and mammalian cell (s) to be multiplied / cloned are NSO cells.
- the present invention provides for the first time hamster cells and mouse myeloma cells, preferably NSO cells, as feeder cells. For this reason, the present invention also relates to the use of a hamster cell or a mouse myeloma cell of the NSO type as feeder cell. Methods for producing corresponding feeder cells are described in more detail in the exemplary embodiments.
- the corresponding hamster or mouse myeloma feeder cells can in principle be prepared by chemical or physical processes known to the person skilled in the art, for example by treatment with mitomycin C (Azirino [2 ', 3': 3,4] pyrrolo [1, 2-a ] indole-4,7-dione, 6-amino-8 - [[(aminocarbonyl) oxy] methyl] -1, 1a, 2,8,8a, 8b-hexahydro-8a-methoxy-5-methyl-, [1aR - (1a.alpha., 8.
- mitomycin C Azirino [2 ', 3': 3,4] pyrrolo [1, 2-a ] indole-4,7-dione, 6-amino-8 - [[(aminocarbonyl) oxy] methyl] -1, 1a, 2,8,8a, 8b-hexahydro-8a-methoxy-5-methyl-, [1aR - (1
- the present invention therefore relates to the use of chemically or physically inactivated feeder cells.
- the term “inactivated” means that the cells are limited in their ability to divide, preferably have lost them, but are also still vital. This means that the cells still have metabolic activities such as, for example, the synthesis and secretion of growth factors for a specific one
- the corresponding feeder cells are feeder cells which are adapted to serum-free culture conditions.
- the feeders are -Cells around CHO, BHK or NSO cells as well as descendants / derivatives of these cell lines.
- all cells mentioned in this application can be used as feeder cells after corresponding inactivation.
- the present invention further relates to compositions consisting of a serum-free cell culture medium, less than five divisible mammalian cells, preferably four, three, two or one (1) divisible mammalian cell (s) and feeder cells which are autologous to the divisible mammalian cells.
- the corresponding composition contains only (1) one or two divisible mammalian cells.
- the corresponding composition contains only one (1) individual divisible mammalian cell.
- compositions contain hamster cells, preferably of the subfamily Cricetinae, particularly preferably of the genus Cricetulus or Mesocricetus, as feeder cells, if the divisible mammalian cell (s) is CHO or BHK cells or derivatives / derivatives is about this.
- a preferred composition other than feeder cells contains mouse cells, preferably the Murinae subfamily, particularly preferably the Mus genus, if the divisible mammalian cell (s) are mouse hybridoma cells, preferably NSO cells or Derivatives / descendants of this.
- compositions are characterized in that the composition contains CHO cells as feeder cells if the divisible mammalian cell (s) are CHO cells, that the composition contains BHK cells as feeder cells if the divisible mammalian cell (s) are BHK cells and the composition contains NSO cells as feeder cells if the divisible mammalian cell (s) are NSO cells.
- compositions according to the invention which allow fewer than 5, preferably 4, 3, 2 or 1 production-relevant hamster cell (s), such as, for example, CHO or BHK cell (s), and production-relevant mouse myeloma cells, such as, for example NSO cell (s) in To store and multiply the presence of feeder cells from mammals under serum-free conditions.
- production-relevant hamster cell such as, for example, CHO or BHK cell (s)
- production-relevant mouse myeloma cells such as, for example NSO cell (s)
- serum-free, protein-free or chemically defined media are, for example, the commercially available media Ham 's F12 (Sigma, Deisenhofen, DE), RPMI-1640 (Sigma), Dulbecco 's Modified Eagle 's Medium (DMEM; Sigma), Minimal Essential Medium (MEM; Sigma), Iscove 's Modified Dulbecco 's Medium (IMDM; Sigma), CD-CHO (Invitrogen, Carlsbad, Ca., USA), CHO-S-SFMII (Invitrogen), serum-free CHO medium ( Sigma) and protein-free CHO medium (Sigma).
- Each of these media can optionally be supplemented with various compounds, for example hormones and / or other growth factors (for example insulin, transferrin, epidermal growth factor, insulin-like growth factor), salts (for example sodium chloride, Calcium, magnesium, phosphate), buffers (e.g. HEPES), nucleosides (e.g. adenosine, thymidine), glutamine, glucose or other equivalent nutrients, antibiotics and / or trace elements.
- hormones and / or other growth factors for example insulin, transferrin, epidermal growth factor, insulin-like growth factor
- salts for example sodium chloride, Calcium, magnesium, phosphate
- buffers e.g. HEPES
- nucleosides e.g. adenosine, thymidine
- glutamine glucose or other equivalent nutrients
- antibiotics and / or trace elements can also be added to the medium.
- the cells CHO-DG44 / dhfr "A (Urlaub et al., 1983) were permanently suspended cells in serum-free CHO-S-SFMII medium supplemented with hypoxanthine and thymidine (Invitrogen GmbH, Düsseldorf, DE) in cell culture bottles at 37 ° C. cultivated in a humid atmosphere and 5% CO 2.
- the cell numbers and the viability were determined using a CEDEX Cell Counter (Innovatis, DE) or by trypan blue staining and the cells were then sown in a concentration of 1-3 ⁇ 10 5 / mL and passages every 2 to 3 days
- recombinant CHO-DG44 / dhfr "/" which contain a fluorescent protein (for example ZS-Green from Zoanthus sp.) or a fluorescent protein and a human or a humanized monoclonal antibody
- the culture of cloned recombinant cells was carried out analogously to these cells, and CHO-S-SFM-II medium (Invitrogen GmbH, Düsseldorf, DE) without hypoxanthine and thymidine was also used as the medium HK can be permanently cultivated as suspension cells in serum-free Opti Pro SFM medium (Invitrogen GmbH, Düsseldorf, DE) in cell culture bottles at 37 ° C in a humid atmosphere and 5% C0 2 .
- the cell counts as well as the viability can be determined with a CEDEX Cell Counter (Innovatis, DE) or by trypan blue staining, the cells then being sown in a concentration of 1 - 3 x 10 5 / mL and passaged every 2 - 3 days. Cloned cells are cultivated analogously to the BHK cells.
- the NSO cells can be permanently cultivated as suspension cells in serum-free hybridoma medium, animal component free medium (Sigma, Aldrich, St. Louis, USA) in cell culture bottles at 37 ° C. in a humid atmosphere and 5% CO 2 .
- the Cell numbers and viability can be determined with a CEDEX Cell Counter (Innovatis, DE) or by trypan blue staining and the cells are then sown in a concentration of 1 - 3 x10 5 / mL and passaged every 2 - 3 days.
- the cultivation of cloned cells is carried out analogously to the cells NSO.
- Hybridoma Medium, Animal component free Medium (Sigma, Aldrich, St. Louis, USA) is used as the medium.
- Serum and protein free growing suspended CHO basic cells (non-transfected cells) were centrifuged at 180g for 10 minutes and adjusted to a cell concentration of 1 x 10 6 / mL in HBSS (Hank's balanced salt solution). The cells were then irradiated with a radioactive radiation source (Cs137 emitter, Gammacell 2000, Molsgaard Medical A / S, Denmark) with an energy dose rate of 4Gy / min. With an irradiation time between 5min and 125min, the energy dose was between 20 and 500 Gy. After the irradiation, the cells were sown with approx.
- a radioactive radiation source Cs137 emitter, Gammacell 2000, Molsgaard Medical A / S, Denmark
- the correspondingly produced feeder cells can be cryopreserved at below - 150 ° C.
- the cryopreservation is carried out using a programmable freezer in the respective cell culture medium (Consarctic BV-25, Consarctic, Schöllkrippen, DE). 10% (v / v) DMSO is added to the media as a cryoprotectant.
- the freezing rate between 0 ° C and -20 ° C is 1 ° C / min, then the temperature is further reduced at 0.4 ° C / min.
- the feeder cells are cryopreserved in the gas phase in liquid nitrogen.
- the automatic cell deposition (single or multi-cell deposition) is carried out with an autoclone unit using a flow cytometer (Coulter EPICS Altra (Beckman-Coulter, Miami, FL, USA)) equipped with an argon laser (488 nm) centrifuged during the exponential growth phase and taken up to a cell concentration of 1 - 1.5 x 10 7 / mL in HBSS.
- the cells are then sorted with the "hypersort option" at a speed of 8000-12000 cells / second according to their position in the scattered light.
- Cells that express a fluorescent protein can alternatively be sorted according to their fluorescence intensity in relation to the intracellularly expressed fluorescent protein.
- the cells are deposited individually in 96-well microtiter plates equipped with feeder cells.
- BHK cells are deposited, for example, in OptiPro SFM Medium (Invitrogen GmbH, Düsseldorf, DE)
- the sorted NSO cells are exemplified in Hybridoma Medium, Animal component free medium (Sigma, Aldrich, St. Louis, USA).
- CHO-S-SFM-II Invitrogen GmbH, Düsseldorf, DE
- a recombinant CHO-DG-44 cell was deposited, which contains a human or a humanized monoclonal antibody and the ZS-Green from Zoanthus sp. co-expressed.
- the cells were sorted as described above with an argon laser at 488nm.
- the CHO-DG-44 cells were cultivated as described under methods “cultivation of the cells”.
- the production of the feeder cells was carried out as in methods “production of feeder cells by radiation "described with an energy dose of 20 Gy, 50 Gy, 100 Gy, 200 Gy and 500 Gy, respectively.
- the feeder cells were sown in 96-well microtiter plates with a cell count of approx. 2000 cells / well and stored in an incubation atmosphere. This was followed by automated individual storage with a recombinant CHO-DG-44 cell that expressed a fluorescent protein, as described under methods “automated single cell storage”.
- Example 2 Homogeneity of the recloning of antibody-expressing CHO-DG-44 cells
- FIG. 1 For this purpose, 6 cell pools of transfected antibody-expressing CHO-DG-44 cells were cultivated according to the limited dilution method and in parallel after the automated single cell deposition, as described under "Culturing the cells", and then as under "Automated individual deposition "The resulting clones were cultivated as described under” Culturing the cells "and over the course of three passages of the Product titer was determined by the method “determination of the productivity of recombinantly expressed gene products”. The mean value resulting from these three passages was used to produce the graphic.
- Example 3 High-throughput method for generating high-titer cell clones by combining the expression of fluorescent proteins with FACS-based cell sorting and FACS-based single cell storage
- CHO DG44 cells By transfecting CHO DG44 cells with an expression vector which encodes the bicistronic expression of a product gene (recombinant antibody) and a fluorescent protein (ZS-Green from Zoanthus sp.), Cell pools were contained which contain both the antibody and the fluorescent protein co - express. These cell pools were individually deposited and cultured in microtiter plates in the presence of autologous CHO DG44 feeder cells. The clones were deposited using three different criteria.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020067003371A KR101184572B1 (ko) | 2003-08-19 | 2004-08-17 | 생산 세포를 재클로닝하는 방법 |
JP2006523593A JP5129959B2 (ja) | 2003-08-19 | 2004-08-17 | 生産細胞の再クローン化方法 |
EP04764194A EP1658365B1 (de) | 2003-08-19 | 2004-08-17 | Verfahren zur reklonierung von produktionszellen |
CA2536239A CA2536239C (en) | 2003-08-19 | 2004-08-17 | Method for recloning production cells |
DK04764194T DK1658365T3 (da) | 2003-08-19 | 2004-08-17 | Fremgangsmåde til genkloning af produktionsceller |
DE502004008542T DE502004008542D1 (de) | 2003-08-19 | 2004-08-17 | Verfahren zur reklonierung von produktionszellen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10338531A DE10338531A1 (de) | 2003-08-19 | 2003-08-19 | Verfahren zur Reklonierung von Produktionszellen |
DEDE10338531.2 | 2003-08-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005019442A2 true WO2005019442A2 (de) | 2005-03-03 |
WO2005019442A3 WO2005019442A3 (de) | 2005-10-06 |
Family
ID=34201814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/009204 WO2005019442A2 (de) | 2003-08-19 | 2004-08-17 | Verfahren zur reklonierung von produktionszellen |
Country Status (11)
Country | Link |
---|---|
US (1) | US7833787B2 (de) |
EP (2) | EP1658365B1 (de) |
JP (1) | JP5129959B2 (de) |
KR (1) | KR101184572B1 (de) |
AT (2) | ATE515565T1 (de) |
CA (1) | CA2536239C (de) |
DE (2) | DE10338531A1 (de) |
DK (2) | DK1658365T3 (de) |
ES (2) | ES2368772T3 (de) |
TW (1) | TWI337201B (de) |
WO (1) | WO2005019442A2 (de) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1901068A1 (de) * | 2006-09-15 | 2008-03-19 | Boehringer Ingelheim Pharma GmbH & Co. KG | Methoden zur Selektion von Zellklonen |
WO2008031873A1 (en) * | 2006-09-15 | 2008-03-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methods of selecting cell clones |
WO2013112945A1 (en) | 2012-01-27 | 2013-08-01 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
WO2015001504A2 (en) | 2013-07-04 | 2015-01-08 | Neotope Biosciences Limited | Antibody formulations and methods |
WO2015004633A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize islet-amyloid polypeptide (iapp) |
WO2015004632A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize iapp |
WO2015075635A2 (en) | 2013-11-19 | 2015-05-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
WO2015136471A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
WO2015136470A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2015136469A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2015155694A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
WO2016120810A1 (en) | 2015-01-28 | 2016-08-04 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2016120809A1 (en) | 2015-01-28 | 2016-08-04 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2016120811A1 (en) | 2015-01-28 | 2016-08-04 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017046776A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
WO2017191561A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2017191560A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2017191559A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Tau immunotherapy |
WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2018007924A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2018007922A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2018007923A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
EP3378535A1 (de) | 2011-10-28 | 2018-09-26 | Prothena Biosciences Limited | Alpha-synuklein erkennende humanisierte antikörper |
WO2019064053A1 (en) | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES |
EP3498296A1 (de) | 2012-10-08 | 2019-06-19 | Prothena Biosciences Limited | Antikörper zur erkennung von alpha-synuklein |
WO2020112687A2 (en) | 2018-11-26 | 2020-06-04 | Forty Seven, Inc. | Humanized antibodies against c-kit |
US11926659B2 (en) | 2019-03-03 | 2024-03-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
US11958896B2 (en) | 2017-05-02 | 2024-04-16 | Prothena Biosciences Limited | Antibodies recognizing tau |
US12049498B2 (en) | 2020-06-24 | 2024-07-30 | Prothena Biosciences Limited | Humanized antibodies recognizing sortilin |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060223183A1 (en) * | 2005-03-11 | 2006-10-05 | Bates Steven E | Gamma irradiation of frozen feeder cells |
WO2009115495A1 (de) * | 2008-03-19 | 2009-09-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methode zur steigerung der reklonierungseffizienz |
JP5304275B2 (ja) * | 2009-01-29 | 2013-10-02 | Jnc株式会社 | アポクライティン−iiをコードするコドン最適化核酸およびその使用方法 |
HUE045635T2 (hu) | 2009-04-09 | 2020-01-28 | Sartorius Stedim Cellca Gmbh | Eljárás továbbfejlesztett egysejtes klónozásra |
JP5697042B2 (ja) | 2009-11-19 | 2015-04-08 | 国立大学法人 岡山大学 | 遺伝子発現を上昇させるシステム及び該システムを保持したベクター |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002029012A1 (en) * | 2000-10-03 | 2002-04-11 | University Of North Carolina | Processes for clonal growth of hepatic progenitor cells |
US20030032182A1 (en) * | 1999-10-01 | 2003-02-13 | Hiroshi Kubota | Processes for clonal growth of hepatic progenitor cells |
US20030073234A1 (en) * | 2001-10-12 | 2003-04-17 | Michal Amit | Clonal human embryonic stem cell lines and methods of generating same |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
US5008198A (en) | 1984-09-14 | 1991-04-16 | Scripps Clinic And Research Foundation | Merozoite surface glycoproteins |
EP0557459B1 (de) | 1990-11-13 | 1997-10-22 | Immunex Corporation | Bifunktionelle wählbare fusionsgene |
US5459058A (en) * | 1991-03-28 | 1995-10-17 | Benjamin Rich | Cell culture system |
EP0804590A1 (de) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Bifunktionelle selektierbare fusionsgene auf dem cytosin-deaminase (cd) gen beruhend |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
SK286870B6 (sk) | 1998-04-17 | 2009-06-05 | Soci�T� Des Produits Nestl� S.A. | Ľudská keratinocytová bunková línia, in vitro spôsob imortalizácie ľudských kožných buniek, použitie ľudskej bunkovej línie a umelá koža s jej obsahom |
WO2000034325A1 (en) | 1998-12-11 | 2000-06-15 | Clontech Laboratories, Inc. | Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof |
WO2000034326A1 (en) | 1998-12-11 | 2000-06-15 | Clontech Laboratories, Inc. | Fluorescent proteins from non-bioluminescent species of class anthozoa, genes encoding such proteins and uses thereof |
ES2361971T3 (es) | 1998-12-11 | 2011-06-24 | Clontech Laboratories Inc. | Proteínas fluorescentes de especies sin bioluminiscencia de la clase de los antozoos, genes codificantes de tales proteínas y sus usos. |
WO2001004306A1 (en) | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Expression vectors and methods |
WO2001011021A1 (de) * | 1999-08-05 | 2001-02-15 | Baxter Aktiengesellschaft | Rekombinanter stabiler zellklon, seine herstellung und verwendung |
JP2003527833A (ja) | 1999-10-14 | 2003-09-24 | クロンテック・ラボラトリーズ・インコーポレーテッド | 花虫類に由来する発色団/蛍光体、およびそれらの使用法 |
-
2003
- 2003-08-19 DE DE10338531A patent/DE10338531A1/de not_active Ceased
-
2004
- 2004-08-17 CA CA2536239A patent/CA2536239C/en not_active Expired - Fee Related
- 2004-08-17 ES ES08151018T patent/ES2368772T3/es not_active Expired - Lifetime
- 2004-08-17 JP JP2006523593A patent/JP5129959B2/ja not_active Expired - Fee Related
- 2004-08-17 EP EP04764194A patent/EP1658365B1/de not_active Expired - Lifetime
- 2004-08-17 DK DK04764194T patent/DK1658365T3/da active
- 2004-08-17 EP EP08151018A patent/EP1918364B1/de not_active Expired - Lifetime
- 2004-08-17 ES ES04764194T patent/ES2317023T3/es not_active Expired - Lifetime
- 2004-08-17 KR KR1020067003371A patent/KR101184572B1/ko not_active IP Right Cessation
- 2004-08-17 AT AT08151018T patent/ATE515565T1/de active
- 2004-08-17 WO PCT/EP2004/009204 patent/WO2005019442A2/de active Application Filing
- 2004-08-17 DE DE502004008542T patent/DE502004008542D1/de not_active Expired - Lifetime
- 2004-08-17 AT AT04764194T patent/ATE415471T1/de active
- 2004-08-17 DK DK08151018.2T patent/DK1918364T3/da active
- 2004-08-18 TW TW093124872A patent/TWI337201B/zh not_active IP Right Cessation
- 2004-08-19 US US10/922,577 patent/US7833787B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030032182A1 (en) * | 1999-10-01 | 2003-02-13 | Hiroshi Kubota | Processes for clonal growth of hepatic progenitor cells |
WO2002029012A1 (en) * | 2000-10-03 | 2002-04-11 | University Of North Carolina | Processes for clonal growth of hepatic progenitor cells |
US20030073234A1 (en) * | 2001-10-12 | 2003-04-17 | Michal Amit | Clonal human embryonic stem cell lines and methods of generating same |
Non-Patent Citations (8)
Title |
---|
BATTYE F L ET AL: "Single cell sorting and cloning" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, Bd. 243, Nr. 1-2, 21. September 2000 (2000-09-21), Seiten 25-32, XP004210690 ISSN: 0022-1759 * |
BORRELLI M J ET AL: "EVIDENCE THAT THE FEEDER EFFECT IN MAMMALIAN CELLS IS MEDIATED BY A DIFFUSIBLE SUBSTANCE" INTERNATIONAL JOURNAL OF HYPERTHERMIA, Bd. 5, Nr. 1, 1989, Seiten 99-104, XP008042840 ISSN: 0265-6736 * |
BORTH N ET AL: "Efficient selection of high-producing subclones during gene amplification of recombinant Chinese hamster ovary cells by flow cytometry and cell sorting." BIOTECHNOLOGY AND BIOENGINEERING. 2000-2001, Bd. 71, Nr. 4, 2000, Seiten 266-273, XP002317361 ISSN: 0006-3592 * |
BREZINSKY S C G ET AL: "A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, Bd. 277, Nr. 1-2, 1. Juni 2003 (2003-06-01), Seiten 141-155, XP004430554 ISSN: 0022-1759 * |
ECHCHAKIR H ET AL: "Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung." INTERNATIONAL IMMUNOLOGY. APR 2000, Bd. 12, Nr. 4, April 2000 (2000-04), Seiten 537-546, XP002317362 ISSN: 0953-8178 * |
GREEN BRONWYN J ET AL: "Rapid screening for high-titer retroviral packaging cell lines using an in situ fluorescence assay." HUMAN GENE THERAPY. 10 JUN 2002, Bd. 13, Nr. 9, 10. Juni 2002 (2002-06-10), Seiten 1005-1013, XP002333721 ISSN: 1043-0342 * |
HLINAK A ET AL: "Feeder cells from different sources and conditioned media for recloning of human--mouse and mouse--mouse hybridomas." FOLIA BIOLOGICA. 1988, Bd. 34, Nr. 2, 1988, Seiten 105-117, XP008042737 ISSN: 0015-5500 * |
HUGIN A W: "Cloning of cells with autologous feeder cells" JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, Bd. 205, Nr. 2, 14. Juli 1997 (1997-07-14), Seiten 211-212, XP004126294 ISSN: 0022-1759 * |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008031873A1 (en) * | 2006-09-15 | 2008-03-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methods of selecting cell clones |
EP1901068A1 (de) * | 2006-09-15 | 2008-03-19 | Boehringer Ingelheim Pharma GmbH & Co. KG | Methoden zur Selektion von Zellklonen |
EP3378535A1 (de) | 2011-10-28 | 2018-09-26 | Prothena Biosciences Limited | Alpha-synuklein erkennende humanisierte antikörper |
WO2013112945A1 (en) | 2012-01-27 | 2013-08-01 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
EP3498296A1 (de) | 2012-10-08 | 2019-06-19 | Prothena Biosciences Limited | Antikörper zur erkennung von alpha-synuklein |
EP3689904A1 (de) | 2013-03-13 | 2020-08-05 | Prothena Biosciences Limited | Tau immuntherapie |
US11643457B2 (en) | 2013-03-13 | 2023-05-09 | Prothena Biosciences Limited | Tau immunotherapy |
WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
WO2015001504A2 (en) | 2013-07-04 | 2015-01-08 | Neotope Biosciences Limited | Antibody formulations and methods |
EP3524264A1 (de) | 2013-07-04 | 2019-08-14 | Prothena Biosciences Limited | Antikörperreinigungsverfahren |
WO2015004632A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize iapp |
WO2015004633A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize islet-amyloid polypeptide (iapp) |
WO2015075635A2 (en) | 2013-11-19 | 2015-05-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
WO2015136470A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
WO2015136471A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
WO2015136469A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2015155694A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
EP4134379A1 (de) | 2015-01-28 | 2023-02-15 | Prothena Biosciences Limited | Anti-transthyretin-antikörper |
WO2016120810A1 (en) | 2015-01-28 | 2016-08-04 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2016120811A1 (en) | 2015-01-28 | 2016-08-04 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2016120809A1 (en) | 2015-01-28 | 2016-08-04 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017046776A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
US11584791B2 (en) | 2016-05-02 | 2023-02-21 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2017191559A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Tau immunotherapy |
WO2017191561A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2017191560A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2018007924A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2018007923A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2018007922A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US11958896B2 (en) | 2017-05-02 | 2024-04-16 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2019064053A1 (en) | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES |
WO2020112687A2 (en) | 2018-11-26 | 2020-06-04 | Forty Seven, Inc. | Humanized antibodies against c-kit |
US11926659B2 (en) | 2019-03-03 | 2024-03-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
US12049498B2 (en) | 2020-06-24 | 2024-07-30 | Prothena Biosciences Limited | Humanized antibodies recognizing sortilin |
US12049497B2 (en) | 2020-06-24 | 2024-07-30 | Prothena Biosciences Limited | Antibodies recognizing sortilin |
Also Published As
Publication number | Publication date |
---|---|
EP1918364B1 (de) | 2011-07-06 |
EP1918364A3 (de) | 2008-05-14 |
ATE415471T1 (de) | 2008-12-15 |
TWI337201B (en) | 2011-02-11 |
WO2005019442A3 (de) | 2005-10-06 |
EP1918364A2 (de) | 2008-05-07 |
CA2536239A1 (en) | 2005-03-03 |
EP1658365B1 (de) | 2008-11-26 |
ES2317023T3 (es) | 2009-04-16 |
US20050059146A1 (en) | 2005-03-17 |
US7833787B2 (en) | 2010-11-16 |
JP2007502608A (ja) | 2007-02-15 |
ES2368772T3 (es) | 2011-11-22 |
CA2536239C (en) | 2014-05-27 |
JP5129959B2 (ja) | 2013-01-30 |
ATE515565T1 (de) | 2011-07-15 |
DK1918364T3 (da) | 2011-08-29 |
EP1658365A2 (de) | 2006-05-24 |
DK1658365T3 (da) | 2009-02-02 |
KR20060065706A (ko) | 2006-06-14 |
DE502004008542D1 (de) | 2009-01-08 |
KR101184572B1 (ko) | 2012-09-21 |
DE10338531A1 (de) | 2005-04-07 |
TW200516148A (en) | 2005-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1658365B1 (de) | Verfahren zur reklonierung von produktionszellen | |
JP2007502608A6 (ja) | 生産細胞の再クローン化方法 | |
US10907186B2 (en) | Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins | |
EP2049671A1 (de) | Regulatorische nukleinsäureelemente | |
US11299760B2 (en) | Use of monensin to regulate glycosylation of recombinant proteins | |
EP1567648A1 (de) | Expressionsvektor, verfahren zur herstellung von heterologen genprodukten und selektionsverfahren für hochproduzierende rekombinante zellen | |
US8669109B2 (en) | Methods of producing proteins in Chinese hamster ovary (CHO) cells | |
US8597909B2 (en) | Use of HSA-producing cells | |
US10106829B2 (en) | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins | |
EP2257620A1 (de) | Methode zur steigerung der reklonierungseffizienz | |
EA047078B1 (ru) | Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004764194 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2536239 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006523593 Country of ref document: JP Ref document number: 1020067003371 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 594/KOLNP/2006 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004764194 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067003371 Country of ref document: KR |